AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
CLINICAL PHARMACOKINETICS OF IRINOTECAN
Authors: CHABOT GG
Citation: Gg. Chabot, CLINICAL PHARMACOKINETICS OF IRINOTECAN, Clinical pharmacokinetics, 33(4), 1997, pp. 245-259
SYNTHESIS AND IN-VITRO CYTOTOXICITY OF A SERIES OF 3-AMINOFLAVONES
Authors: DAUZONNE D FOLLEAS B MARTINEZ L CHABOT GG
Citation: D. Dauzonne et al., SYNTHESIS AND IN-VITRO CYTOTOXICITY OF A SERIES OF 3-AMINOFLAVONES, European journal of medicinal chemistry, 32(1), 1997, pp. 71-82
EXPRESSION AND INDUCIBILITY OF CYTOCHROME-P450-3A9 (CYP3A9) AND OTHERMEMBERS OF THE CYP3A-SUBFAMILY IN RAT-LIVER
Authors: MAHNKE Z STROTKAMP D ROOS PH HANSTEIN WG CHABOT GG NEF P
Citation: Z. Mahnke et al., EXPRESSION AND INDUCIBILITY OF CYTOCHROME-P450-3A9 (CYP3A9) AND OTHERMEMBERS OF THE CYP3A-SUBFAMILY IN RAT-LIVER, Archives of biochemistry and biophysics, 337(1), 1997, pp. 62-68
EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE
Authors: BISSERY MC VRIGNAUD P LAVELLE F CHABOT GG
Citation: Mc. Bissery et al., EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE, Anti-cancer drugs, 7(4), 1996, pp. 437-460
PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS
Authors: ABIGERGES D ARMAND JP CHABOT GG BRUNO R BISSERY MC BAYSSAS M KLINKALAKL M CLAVEL M CATIMEL G
Citation: D. Abigerges et al., PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS, Anti-cancer drugs, 7(2), 1996, pp. 166-174
ETOPOSIDE BIOAVAILABILITY AFTER ORAL-ADMINISTRATION OF THE PRODRUG ETOPOSIDE PHOSPHATE IN CANCER-PATIENTS DURING A PHASE-I STUDY
Authors: CHABOT GG ARMAND JP TERRET C DEFORNI M ABIGERGES D WINOGRAD B IGWEMEZIE L SCHACTER L KAUL S ROPERS J BONNAY M
Citation: Gg. Chabot et al., ETOPOSIDE BIOAVAILABILITY AFTER ORAL-ADMINISTRATION OF THE PRODRUG ETOPOSIDE PHOSPHATE IN CANCER-PATIENTS DURING A PHASE-I STUDY, Journal of clinical oncology, 14(7), 1996, pp. 2020-2030
IN-VIVO INDUCTION OF CYTOCHROME-P450 CYP3A EXPRESSION IN RAT LEUKOCYTES USING VARIOUS INDUCERS
Authors: MAHNKE A ROOS PH HANSTEIN WG CHABOT GG
Citation: A. Mahnke et al., IN-VIVO INDUCTION OF CYTOCHROME-P450 CYP3A EXPRESSION IN RAT LEUKOCYTES USING VARIOUS INDUCERS, Biochemical pharmacology, 51(11), 1996, pp. 1579-1582
MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN HUMAN NON-HODGKINS-LYMPHOMASSENSITIVE OR RESISTANT TO CHEMOTHERAPY
Authors: RIBRAG V MASSAAD L JANOT F MORIZET J GOUYETTE A CHABOT GG
Citation: V. Ribrag et al., MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN HUMAN NON-HODGKINS-LYMPHOMASSENSITIVE OR RESISTANT TO CHEMOTHERAPY, Leukemia & lymphoma, 18(3-4), 1995, pp. 303-310
PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDDAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: CATIMEL G CHABOT GG GUASTALLA JP DUMORTIER A COTE C ENGEL C GOUYETTE A MATHIEUBOUE A MAHJOUBI M CLAVEL M
Citation: G. Catimel et al., PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDDAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS, Annals of oncology, 6(2), 1995, pp. 133-140
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS
Authors: CHABOT GG ABIGERGES D CATIMEL G CULINE S DEFORNI R EXTRA JM MAHJOUBI H HERAIT P ARMAND JP BUGAT R CLAVEL M MARTY ME
Citation: Gg. Chabot et al., POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS, Annals of oncology, 6(2), 1995, pp. 141-151
PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS
Authors: ABIGERGES D CHABOT GG ARMAND JP HERAIT P GOUYETTE A GANDIA D
Citation: D. Abigerges et al., PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS, Journal of clinical oncology, 13(1), 1995, pp. 210-221
LIMITED SAMPLING MODELS FOR SIMULTANEOUS ESTIMATION OF THE PHARMACOKINETICS OF IRINOTECAN AND ITS ACTIVE METABOLITE SN-38
Authors: CHABOT GG
Citation: Gg. Chabot, LIMITED SAMPLING MODELS FOR SIMULTANEOUS ESTIMATION OF THE PHARMACOKINETICS OF IRINOTECAN AND ITS ACTIVE METABOLITE SN-38, Cancer chemotherapy and pharmacology, 36(6), 1995, pp. 463-472
PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION
Authors: DEFORNI M CHABOT GG ARMAND JP GOUYETTE A KLINKALAK M RECONDO G
Citation: M. Deforni et al., PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION, Cancer chemotherapy and pharmacology, 35(3), 1995, pp. 219-224
IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA
Authors: ABIGERGES D ARMAND JP CHABOT GG DACOSTA L FADEL E COTE C HERAIT P GANDIA D
Citation: D. Abigerges et al., IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA, Journal of the National Cancer Institute, 86(6), 1994, pp. 446-449
THYMIDYLATE SYNTHASE ACTIVITY, FOLATES, AND GLUTATHIONE SYSTEM IN HEAD AND NECK-CARCINOMA AND ADJACENT TISSUES
Authors: PARISE O JANOT F LUBOINSKI B MASSAAD L ALBIN N TOUSSAINT C VERJUS MA BONNAY M GOUYETTE A CHABOT GG
Citation: O. Parise et al., THYMIDYLATE SYNTHASE ACTIVITY, FOLATES, AND GLUTATHIONE SYSTEM IN HEAD AND NECK-CARCINOMA AND ADJACENT TISSUES, Head & neck, 16(2), 1994, pp. 158-164
PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES
Authors: MUNCK JN ROUGIER P CHABOT GG RAMIREZ LH BOGNEL C LUMBROSO J HERAIT P ELIAS D LASSER P GOUYETTE A
Citation: Jn. Munck et al., PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES, European journal of cancer, 30A(3), 1994, pp. 289-294
PHASE I II TRIAL OF CONTINUOUS-INFUSION VINORELBINE FOR ADVANCED BREAST-CANCER/
Authors: TOUSSAINT C IZZO J SPIELMANN M MERLE S MAYLEVIN F ARMAND JP LACOMBE D TURSZ T SUNDERLAND M CHABOT GG CVITKOVIC E
Citation: C. Toussaint et al., PHASE I II TRIAL OF CONTINUOUS-INFUSION VINORELBINE FOR ADVANCED BREAST-CANCER/, Journal of clinical oncology, 12(10), 1994, pp. 2102-2112
INFLUENCE OF TUMOR SIZE ON THE MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN MOUSE COLON ADENOCARCINOMA CO38
Authors: MASSAAD L CHABOT GG TOUSSAINT C KOSCIELNY S MORIZET J BISSERY MC GOUYETTE A
Citation: L. Massaad et al., INFLUENCE OF TUMOR SIZE ON THE MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN MOUSE COLON ADENOCARCINOMA CO38, Cancer chemotherapy and pharmacology, 34(6), 1994, pp. 497-502
FACTORS INVOLVED IN CLINICAL-PHARMACOLOGY VARIABILITY IN ONCOLOGY
Authors: CHABOT GG
Citation: Gg. Chabot, FACTORS INVOLVED IN CLINICAL-PHARMACOLOGY VARIABILITY IN ONCOLOGY, Anticancer research, 14(6A), 1994, pp. 2269-2272
PRINCIPAL DRUG-METABOLIZING ENZYME-SYSTEMS IN L1210 LEUKEMIA SENSITIVE OR RESISTANT TO BCNU IN-VIVO
Authors: RIBRAG V MASSAAD L JANOT F BISSERY MC PARISE O GOUYETTE A CHABOT GG
Citation: V. Ribrag et al., PRINCIPAL DRUG-METABOLIZING ENZYME-SYSTEMS IN L1210 LEUKEMIA SENSITIVE OR RESISTANT TO BCNU IN-VIVO, Leukemia research, 18(11), 1994, pp. 829-835
PHASE-I AND PHARMACOKINETIC STUDY OF THE CAMPTOTHECIN DERIVATIVE IRINOTECAN, ADMINISTERED ON A WEEKLY SCHEDULE IN CANCER-PATIENTS
Authors: DEFORNI M BUGAT R CHABOT GG CULINE S EXTRA JM GOUYETTE A MADELAINE I MARTY ME MATHIEUBOUE A
Citation: M. Deforni et al., PHASE-I AND PHARMACOKINETIC STUDY OF THE CAMPTOTHECIN DERIVATIVE IRINOTECAN, ADMINISTERED ON A WEEKLY SCHEDULE IN CANCER-PATIENTS, Cancer research, 54(16), 1994, pp. 4347-4354
PHASE-I AND PHARMACOKINETIC STUDY OF BREQUINAR (DUP-785 NSC-368390) IN CANCER-PATIENTS
Authors: DEFORNI M CHABOT GG ARMAND JP FONTANA X RECONDO G DOMENGE C CARDE P BARBU M GOUYETTE A
Citation: M. Deforni et al., PHASE-I AND PHARMACOKINETIC STUDY OF BREQUINAR (DUP-785 NSC-368390) IN CANCER-PATIENTS, European journal of cancer, 29A(7), 1993, pp. 983-988
TEST DOSE-GUIDED ADMINISTRATION OF CISPLATIN IN AN ANEPHRIC PATIENT -A CASE-REPORT
Authors: RIBRAG V DROZ JP MORIZET J LECLERCQ B GOUYETTE A CHABOT GG
Citation: V. Ribrag et al., TEST DOSE-GUIDED ADMINISTRATION OF CISPLATIN IN AN ANEPHRIC PATIENT -A CASE-REPORT, Annals of oncology, 4(8), 1993, pp. 679-682
PRINCIPAL XENOBIOTIC-METABOLIZING ENZYME-SYSTEMS IN HUMAN HEAD AND NECK SQUAMOUS-CELL CARCINOMA
Authors: JANOT F MASSAAD L RIBRAG V DEWAZIERS I BEAUNE PH LUBOINSKI B PARISE O GOUYETTE A CHABOT GG
Citation: F. Janot et al., PRINCIPAL XENOBIOTIC-METABOLIZING ENZYME-SYSTEMS IN HUMAN HEAD AND NECK SQUAMOUS-CELL CARCINOMA, Carcinogenesis, 14(7), 1993, pp. 1279-1283
MAIN DRUG-METABOLIZING AND CARCINOGEN-METABOLIZING ENZYME-SYSTEMS IN HUMAN NONSMALL CELL LUNG-CANCER AND PERITUMORAL TISSUES
Authors: TOUSSAINT C ALBIN N MASSAAD L GRUNENWALD D PARISE O MORIZET J GOUYETTE A CHABOT GG
Citation: C. Toussaint et al., MAIN DRUG-METABOLIZING AND CARCINOGEN-METABOLIZING ENZYME-SYSTEMS IN HUMAN NONSMALL CELL LUNG-CANCER AND PERITUMORAL TISSUES, Cancer research, 53(19), 1993, pp. 4608-4612
Risultati: 1-25 | 26-27